Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash & Equivalents (2016 - 2019)

Historic Cash & Equivalents for Soleno Therapeutics (SLNO) over the last 7 years, with Q3 2019 value amounting to $11.2 million.

  • Soleno Therapeutics' Cash & Equivalents rose 962.98% to $11.2 million in Q3 2019 from the same period last year, while for Sep 2019 it was $11.2 million, marking a year-over-year increase of 962.98%. This contributed to the annual value of $23.1 million for FY2018, which is 3508.19% up from last year.
  • Soleno Therapeutics' Cash & Equivalents amounted to $11.2 million in Q3 2019, which was up 962.98% from $15.5 million recorded in Q2 2019.
  • In the past 5 years, Soleno Therapeutics' Cash & Equivalents ranged from a high of $23.1 million in Q4 2018 and a low of $2.5 million during Q2 2016
  • For the 5-year period, Soleno Therapeutics' Cash & Equivalents averaged around $10.1 million, with its median value being $9.5 million (2015).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 727500.0% in 2015, then plummeted by 6677.29% in 2016.
  • Over the past 5 years, Soleno Therapeutics' Cash & Equivalents (Quarter) stood at $5.5 million in 2015, then plummeted by 50.39% to $2.7 million in 2016, then surged by 527.29% to $17.1 million in 2017, then surged by 35.08% to $23.1 million in 2018, then crashed by 51.4% to $11.2 million in 2019.
  • Its Cash & Equivalents was $11.2 million in Q3 2019, compared to $15.5 million in Q2 2019 and $19.4 million in Q1 2019.